|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
TW200838559A
(en)
*
|
2006-11-29 |
2008-10-01 |
Imclone Systems Inc |
Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
|
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
|
BRPI0919879A2
(pt)
|
2008-10-29 |
2016-02-16 |
Wyeth Llc |
métodos para purificação de moléculas de ligação a antígeno de domínio único
|
|
CA2738243C
(en)
*
|
2008-10-29 |
2020-09-29 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
|
JP5933975B2
(ja)
*
|
2008-11-12 |
2016-06-15 |
メディミューン，エルエルシー |
抗体製剤
|
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
NZ597692A
(en)
|
2008-12-12 |
2013-08-30 |
Boehringer Ingelheim Int |
Anti-IGF antibodies
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
|
US20120076779A1
(en)
*
|
2010-09-17 |
2012-03-29 |
Baxter Healthcare S.A. |
STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
|
|
BR112013011176A2
(pt)
|
2010-11-05 |
2020-09-01 |
Novartis Ag |
métodos de tratamento de artrite reumatoide usando antagonistas de il-17
|
|
EA201992617A1
(ru)
*
|
2011-10-26 |
2020-03-10 |
Амген Инк. |
Способы уменьшения или устранения модификации и разложения белка, обусловленных воздействием уф-излучения
|
|
RS63930B1
(sr)
|
2011-10-28 |
2023-02-28 |
Prothena Biosciences Ltd |
Humanizovana antitela koja prepoznaju alfa-sinuklein
|
|
DK2807188T3
(da)
|
2012-01-27 |
2019-10-07 |
Prothena Biosciences Ltd |
Humaniserede antistoffer, der genkender alpha-synuclein
|
|
AR091902A1
(es)
*
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
|
AR092862A1
(es)
*
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
AR094821A1
(es)
*
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
MX2015006997A
(es)
|
2012-12-26 |
2015-09-23 |
Wockhardt Ltd |
Composicion farmaceutica.
|
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
NL1040254C2
(en)
*
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
|
US10513555B2
(en)
*
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
CA2944402A1
(en)
|
2014-04-08 |
2015-10-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
|
CN107406506A
(zh)
|
2014-12-04 |
2017-11-28 |
詹森生物科技公司 |
用于治疗急性髓系白血病的抗cd38抗体
|
|
ES2763309T3
(es)
*
|
2015-02-09 |
2020-05-28 |
UCB Biopharma SRL |
Formulación farmacéutica que comprende anticuerpos
|
|
EA201792546A1
(ru)
|
2015-05-20 |
2018-04-30 |
Янссен Байотек, Инк. |
Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
|
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
CA3004152C
(en)
*
|
2015-11-03 |
2024-04-16 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-cd38 antibodies and their uses
|
|
JP6992262B2
(ja)
*
|
2016-03-31 |
2022-02-15 |
東ソー株式会社 |
変性抗体測定試薬の製造方法
|
|
US20190233533A1
(en)
|
2016-06-28 |
2019-08-01 |
Umc Utrecht Holding B.V. |
Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
|
|
US10799597B2
(en)
|
2017-04-03 |
2020-10-13 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
MA50514A
(fr)
|
2017-10-31 |
2020-09-09 |
Janssen Biotech Inc |
Méthodes de traitement du myélome multiple à haut risque
|
|
CN120241997A
(zh)
|
2019-02-18 |
2025-07-04 |
伊莱利利公司 |
治疗性抗体制剂
|
|
CN112206320B
(zh)
*
|
2019-07-12 |
2025-02-25 |
鲁南制药集团股份有限公司 |
一种cd47单克隆抗体冻干粉制剂及其制备工艺
|
|
EP4159236A4
(en)
|
2020-05-29 |
2024-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing formulation
|
|
CN113967195A
(zh)
*
|
2020-07-22 |
2022-01-25 |
三生国健药业（上海）股份有限公司 |
抗her2/pd1双特异性抗体冻干制剂及其制备方法
|